ICON Public Limited (NASDAQ:ICLR) Receives $283.92 Average PT from Analysts

ICON Public Limited (NASDAQ:ICLR) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $281.00.

ICLR has been the subject of a number of recent research reports. Leerink Partners restated an “outperform” rating and issued a $255.00 price objective (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Robert W. Baird decreased their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Truist Financial decreased their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. decreased their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

Hedge Funds Weigh In On ICON Public

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Foyston Gordon & Payne Inc boosted its position in shares of ICON Public by 27.3% during the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock worth $10,845,000 after purchasing an additional 11,089 shares in the last quarter. Captrust Financial Advisors lifted its position in ICON Public by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock valued at $7,403,000 after acquiring an additional 701 shares in the last quarter. State of Tennessee Department of Treasury lifted its position in ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock valued at $33,333,000 after acquiring an additional 1,600 shares in the last quarter. Motley Fool Wealth Management LLC lifted its position in ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after acquiring an additional 1,466 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 128.2% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 655 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $189.63 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a 52 week low of $181.51 and a 52 week high of $347.72. The firm has a market cap of $15.64 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. The firm’s fifty day moving average is $202.22 and its 200-day moving average is $242.16.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. Sell-side analysts predict that ICON Public will post 13.38 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.